Month: September 2026

New expert-led services platform will help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs across the full care delivery lifecycle

PHILADELPHIA, Pa., and LOUVAIN-LA-NEUVE, Belgium, 28 September 2026, 7 a.m. CEST — Penn Medicine and IBA today announced the formation of Noventra Oncology Alliance, a new joint venture designed to help healthcare providers successfully develop, implement, and optimize proton therapy and advanced radiation oncology programs. The new company will provide an integrated service offering spanning strategic and financial planning, clinical readiness, program implementation, and long-term operational performance.

The new company brings together the clinical, operational, research, and education expertise of Penn Medicine with IBA’s global leadership in proton therapy technology, project development, and implementation capabilities. The joint venture will provide integrated advisory and lifecycle support services that help healthcare organizations navigate the complexities of developing and sustaining successful proton therapy programs.

As proton therapy becomes an increasingly important component of comprehensive cancer care, health systems around the world are seeking to expand access while ensuring clinical excellence and financial sustainability. However, developing and operating a successful proton therapy program requires more than equipment acquisition. Organizations must address challenges related to strategic planning, capital investment, reimbursement, workforce development, clinical readiness, operational performance, research infrastructure, and long-term program growth.

“By combining Penn Medicine’s decades of experience building and operating one of the world’s leading proton therapy programs with IBA’s expertise in proton therapy technology and implementation, we are creating a unique platform to help healthcare organizations deliver exceptional care to patients while building sustainable, high-performing oncology programs,” said James Metz, MD, chair of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine.

“A center that is unable to treat patients at scale or operate sustainably ultimately falls short of its purpose. By bringing together IBA’s global expertise in proton therapy technology and project implementation with Penn Medicine’s clinical and operational leadership, Noventra Oncology Alliance helps organizations reduce the clinical, operational, and financial risks associated with developing advanced radiation oncology programs. It will also be key to reinforcing the value of this technology in cancer treatment and accelerating its broader adoption” added Henri de Romrée, Deputy CEO of IBA.

Unlike traditional advisory models, the joint venture combines the perspectives of a world-leading clinical operator and the global leader in proton therapy technology, creating a single partner that can support organizations from initial strategy through long-term operational excellence.

Visit Noventra’s website or IBA’s booth (#843) and Penn Medicine’s booth (#1722) during the ASTRO Annual Meeting 2026 in Boston to learn more about Noventra’s services.

***ENDS***

About Penn Medicine

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

CONTACTS
Thomas Pevenage
Investor relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

Attachment

• 260928-Noventra-JV-PennM-IBA-EN

New expert-led services platform will help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs across the full care delivery lifecycle

PHILADELPHIA, Pa., and LOUVAIN-LA-NEUVE, Belgium, 28 September 2026, 7 a.m. CEST — Penn Medicine and IBA today announced the formation of Noventra Oncology Alliance, a new joint venture designed to help healthcare providers successfully develop, implement, and optimize proton therapy and advanced radiation oncology programs. The new company will provide an integrated service offering spanning strategic and financial planning, clinical readiness, program implementation, and long-term operational performance.

The new company brings together the clinical, operational, research, and education expertise of Penn Medicine with IBA’s global leadership in proton therapy technology, project development, and implementation capabilities. The joint venture will provide integrated advisory and lifecycle support services that help healthcare organizations navigate the complexities of developing and sustaining successful proton therapy programs.

As proton therapy becomes an increasingly important component of comprehensive cancer care, health systems around the world are seeking to expand access while ensuring clinical excellence and financial sustainability. However, developing and operating a successful proton therapy program requires more than equipment acquisition. Organizations must address challenges related to strategic planning, capital investment, reimbursement, workforce development, clinical readiness, operational performance, research infrastructure, and long-term program growth.

“By combining Penn Medicine’s decades of experience building and operating one of the world’s leading proton therapy programs with IBA’s expertise in proton therapy technology and implementation, we are creating a unique platform to help healthcare organizations deliver exceptional care to patients while building sustainable, high-performing oncology programs,” said James Metz, MD, chair of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine.

“A center that is unable to treat patients at scale or operate sustainably ultimately falls short of its purpose. By bringing together IBA’s global expertise in proton therapy technology and project implementation with Penn Medicine’s clinical and operational leadership, Noventra Oncology Alliance helps organizations reduce the clinical, operational, and financial risks associated with developing advanced radiation oncology programs. It will also be key to reinforcing the value of this technology in cancer treatment and accelerating its broader adoption” added Henri de Romrée, Deputy CEO of IBA.

Unlike traditional advisory models, the joint venture combines the perspectives of a world-leading clinical operator and the global leader in proton therapy technology, creating a single partner that can support organizations from initial strategy through long-term operational excellence.

Visit Noventra’s website or IBA’s booth (#843) and Penn Medicine’s booth (#1722) during the ASTRO Annual Meeting 2026 in Boston to learn more about Noventra’s services.

***ENDS***

About Penn Medicine

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

CONTACTS
Thomas Pevenage
Investor relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

Attachment

• 260928-Noventra-JV-PennM-IBA-EN

H1 2026 RESULTS
DIGITAL MARKETING GROWTH AND IMPROVED PROFITABILITY

• Revenue: €121.9m (+3.9%)
• Net revenue: €90.3m (+2.2%)
• Restated EBITDA: €11.9m (+11.7%)
• Net income (Group share): €6.1m (+58.9%), representing 6.7% of net revenue
• Continued European expansion in Communication and Data Marketing

Paris, September 28, 2026 (7:00 a.m.) – DEKUPLE Group, an international Communication and Data Marketing company, delivered disciplined growth and significantly improved profitability in the first half of 2026.

Bertrand Laurioz, Chairman and Chief Executive Officer of Dekuple Group, said:
“In a persistently demanding environment, DEKUPLE Group continues to deliver disciplined growth while significantly improving profitability. Restated EBITDA increased by 11.7% to €11.9m, bringing the EBITDA margin to 13.2% of net revenue, up 111 basis points compared with a challenging first half of 2025. EBIT increased by 25.3% while net income (Group share) rose by 58.9%.

These results reflect the impact of the investments made in recent years in our expertise, technologies and international development, and reinforce our profitable growth trajectory.

This improvement is notably based on the ramp-up of Digital Marketing, the Group’s main growth driver, and the increasing contribution of our international operations. This momentum also reflects the benefits of the integrated model we are building by bringing together our Consulting, Agencies and Solutions expertise and developing synergies between data, marketing technologies, creativity and artificial intelligence. We are therefore gradually becoming able to further industrialize our offerings, increase their added value and better support our clients across all their marketing needs.

At the same time, we are continuing to manage our historical businesses selectively. In Magazines, we are continuing to digitalize our operations and focusing investments on the highest value-creating levers in a structurally declining press market. With regard to Insurance, the strategic review under way should enable us to identify the most appropriate options to support its long-term development as part of our Ambition 2030 plan.

The marketing industry is rapidly evolving towards more integrated and increasingly performance-oriented models. Advertisers expect their partners to combine strategic expertise, strong command of data, technology and execution capabilities, while providing increasingly precise measurements of investment performance. We have chosen to anticipate this shift by building a multi-expertise model capable of interconnecting these different skills and mobilizing them toward a single objective: creating more value for our clients.

Building on this momentum and a solid financial structure, we approach the second half of the year with confidence. Our priority is clear: continue rolling out Ambition 2030, accelerate our expansion in Europe and strengthen synergies between our businesses in order to become a major growth partner for brands.”

First-half highlights

In the first half of 2026, DEKUPLE Group continued its growth trajectory, supported by the strong performance of its Digital Marketing activities, accelerated international development and continued organic growth.

Digital Marketing activities represented 72.7% of consolidated revenue, compared with 69.6% one year earlier. Their net revenue increased by 8.4%, including 6.0% on a like-for-like basis, driven by strong momentum in Consulting & Technology and Agencies & Solutions.

This momentum was accompanied by strong growth in international activities, whose net revenue increased by 37.1%. International operations now represent 15.3% of Group net revenue, compared with 11.4% one year earlier. The Group also continued to pursue its international external growth strategy, notably through the creation of Das Kapital DEKUPLE Group in the Middle East and the acquisition of Subko & Co in Poland, with their results consolidated from July 1, 2026.

Magazines business recorded a 7.0% decline in net revenue in a structurally declining press market. The Group continues to manage its commercial investments selectively in order to preserve the recurring nature and quality of its revenues.

In Insurance, the strategic review under way is continuing in order to identify the most appropriate options to support the business’s long-term development as part of the Ambition 2030 plan.

First-half results

Consolidated revenue¹ amounted to €121.9m, up 3.9%, while net revenue² reached €90.3m, up 2.2%.

Restated EBITDA³ amounted to €11.9m, up 11.7% compared with a difficult first half of 2025. It represented 13.2% of first-half net revenue, compared with 12.0% in the first half of 2025, an improvement of 111 basis points.

Income from ordinary operations amounted to €8.1m, representing 8.9% of first-half net revenue, compared with €6.5m and 7.4% in the first half of 2025. EBIT also amounted to €8.1m, compared with €6.4m in the first half of 2025. These results notably reflect:

• solid growth in earnings from Agencies & Solutions, driven by the increasing contribution of international operations and the development of technology offerings;
• Consulting profitability remained affected by continued investment in international development, notably in the United States and Spain, and by increased investment in AI and technology, despite a slight improvement in project profitability;
• the lower contribution of the Magazines business to profitability, given the decline in the portfolio.

After a net financial expense of €0.5m and an income tax expense of €1.7m, consolidated net income amounted to €5.8m, representing a net margin of 6.4% of net revenue, compared with 4.2% in the first half of 2025.

After non-controlling interests, net income (Group share) amounted to €6.1m, up 58.9% compared with the first half of 2025.

(€m)	H1 2026	H1 2025	Change
Revenue	121.9	117.4	+3.9%
Net revenue	90.3	88.3	+2.2%
Restated EBITDA	11.9	10.6	+11.7%
As % of net revenue	13.2%	12.0%	+111 bp
Income from ordinary operations	8.1	6.5	+23.5%
As % of net revenue	8.9%	7.4%	+154 bp
EBIT	8.1	6.4	+25.3%
As % of net revenue	8.9%	7.3%	+164 bp
Net financial expense / income	(0.5)	(0.0)
Tax expense	(1.7)	(2.8)
Share of net income from associates	0.0	0.0
Consolidated net income	5.8	3.7	+57.2%
As % of net revenue	6.4%	4.2%	+223 bp
Net income (Group share)	6.1	3.8	+58.9%
As % of net revenue	6.7%	4.3%	+239 bp

Financial position at June 30, 2026

The Group’s shareholders’ equity at June 30, 2026 amounted to €55.6m, up €0.9m compared with December 31, 2025 (€54.7m).

Group cash amounted to €45.3m, compared with €55.0m at December 31, 2025 and €45.8m at June 30, 2025.

Financial debt amounted to €58.0m, down €3.2m compared with year-end 2025 (€61.2m). It includes commitments to buy out minority interests (€20.1m), down from year-end 2025 following additional share acquisitions in certain Group subsidiaries. It also includes €36.4m in bank borrowings, of which €26.2m was drawn under the syndicated credit facility established in November 2025.

Net cash/(debt)⁴ therefore amounted to €(12.7)m, compared with €(6.3)m at year-end 2025 and €(7.8)m at June 30, 2025, reflecting in particular the level of investment and external growth transactions completed over the past twelve months.

Outlook

Building on the momentum recorded in the first half, DEKUPLE Group is continuing to roll out its Ambition 2030 strategic plan, with the aim of accelerating its expansion in Europe while strengthening synergies between its areas of expertise.

The Group is actively developing its digital and international activities, continuing to industrialize marketing performance around the convergence of data, technology, artificial intelligence and creativity, and developing high-value recurring revenues.

Drawing on its financial resources and multi-expertise model, DEKUPLE Group will also continue an active policy of investment in technology and targeted external growth in order to strengthen its European leadership in Communication and Data Marketing.

Additional information

The corporate and consolidated financial statements for the first half of 2026 were approved by the Board of Directors on September 25, 2026. The financial statements have been subject to the usual limited review by the statutory auditors for half-year accounts. The half-year financial report will be published on September 30, 2026, after market close, and will be available on the company website at: https://www.dekuple.com/investisseurs/actualites-documents-presentations/

Next event

Revenue and net revenue for the third quarter of 2026, on November 23, 2026, before market opening.

About Dekuple Group

Dekuple Group is an international player in communication, marketing and data, driven by a unique multi-entrepreneurship model. Its integrated growth platform is built around three interconnected and complementary pillars:

• Advise, with Converteo and its 450 expert consultants
• Create, with its multi-expertise agencies in France and internationally
• Boost, with its Boost Factory bringing together its Data and MarTech solutions

With nearly 70 areas of expertise covering the entire communication and data marketing value chain, the Group supports brands in their differentiation and growth challenges. Its integrated approach, through a full-funnel ecosystem, makes it possible to optimize marketing investments and increase their impact.

Founded in 1972, Dekuple Group is present in Europe, North America, China and the Middle East. Its 1,200 employees support more than 750 major accounts and international mid-sized companies every day. Dekuple is listed on the regulated market of Euronext Paris.

www.dekuple.com

Financial Communications Contacts Actus Finance & Communication Cyril Combe – Analysts – Investors +33 1 53 65 37 94 Fatou-Kiné N’Diaye – Press – Media +33 1 53 67 36 34 dekuple@actus.fr

Dekuple Group Contact Investor Relations & Financial Information + 33 (0)1 41 58 72 03 relations.investisseurs@dekuple.com

---

1 Revenue (determined in line with the French professional status for subscription sales) only include the amount of remuneration paid by magazine publishers; for subscription sales, net sales therefore correspond to a net revenue (formerly gross margin), deducting the cost of magazines sold from the amount of sales recorded. For acquisition and management commissions linked to sales of insurance policies, net sales comprise current and future commissions issued, acquired by the accounting reporting date, net of cancellations.
2 For the digital marketing business, the net revenue (formerly gross margin) represents the total amount of net sales (total invoices issued: fees, commissions and purchases charged back to customers) less the total amount of costs for external purchases made on behalf of customers. It is equal to net sales for the magazines and insurance business lines.

3 EBITDA (earnings before interest, tax, depreciation and amortization) is restated for the IFRS 2 impact of bonus share awards and the IFRS 16 impact relating to the restatement of lease charges.
4 Cash position on the balance sheet net of all financial liabilities.

Attachment

• DEKUPLE_CP_resultats_semestriels_2026_E

H1 2026 RESULTS
DIGITAL MARKETING GROWTH AND IMPROVED PROFITABILITY

• Revenue: €121.9m (+3.9%)
• Net revenue: €90.3m (+2.2%)
• Restated EBITDA: €11.9m (+11.7%)
• Net income (Group share): €6.1m (+58.9%), representing 6.7% of net revenue
• Continued European expansion in Communication and Data Marketing

Paris, September 28, 2026 (7:00 a.m.) – DEKUPLE Group, an international Communication and Data Marketing company, delivered disciplined growth and significantly improved profitability in the first half of 2026.

Bertrand Laurioz, Chairman and Chief Executive Officer of Dekuple Group, said:
“In a persistently demanding environment, DEKUPLE Group continues to deliver disciplined growth while significantly improving profitability. Restated EBITDA increased by 11.7% to €11.9m, bringing the EBITDA margin to 13.2% of net revenue, up 111 basis points compared with a challenging first half of 2025. EBIT increased by 25.3% while net income (Group share) rose by 58.9%.

These results reflect the impact of the investments made in recent years in our expertise, technologies and international development, and reinforce our profitable growth trajectory.

This improvement is notably based on the ramp-up of Digital Marketing, the Group’s main growth driver, and the increasing contribution of our international operations. This momentum also reflects the benefits of the integrated model we are building by bringing together our Consulting, Agencies and Solutions expertise and developing synergies between data, marketing technologies, creativity and artificial intelligence. We are therefore gradually becoming able to further industrialize our offerings, increase their added value and better support our clients across all their marketing needs.

At the same time, we are continuing to manage our historical businesses selectively. In Magazines, we are continuing to digitalize our operations and focusing investments on the highest value-creating levers in a structurally declining press market. With regard to Insurance, the strategic review under way should enable us to identify the most appropriate options to support its long-term development as part of our Ambition 2030 plan.

The marketing industry is rapidly evolving towards more integrated and increasingly performance-oriented models. Advertisers expect their partners to combine strategic expertise, strong command of data, technology and execution capabilities, while providing increasingly precise measurements of investment performance. We have chosen to anticipate this shift by building a multi-expertise model capable of interconnecting these different skills and mobilizing them toward a single objective: creating more value for our clients.

Building on this momentum and a solid financial structure, we approach the second half of the year with confidence. Our priority is clear: continue rolling out Ambition 2030, accelerate our expansion in Europe and strengthen synergies between our businesses in order to become a major growth partner for brands.”

First-half highlights

In the first half of 2026, DEKUPLE Group continued its growth trajectory, supported by the strong performance of its Digital Marketing activities, accelerated international development and continued organic growth.

Digital Marketing activities represented 72.7% of consolidated revenue, compared with 69.6% one year earlier. Their net revenue increased by 8.4%, including 6.0% on a like-for-like basis, driven by strong momentum in Consulting & Technology and Agencies & Solutions.

This momentum was accompanied by strong growth in international activities, whose net revenue increased by 37.1%. International operations now represent 15.3% of Group net revenue, compared with 11.4% one year earlier. The Group also continued to pursue its international external growth strategy, notably through the creation of Das Kapital DEKUPLE Group in the Middle East and the acquisition of Subko & Co in Poland, with their results consolidated from July 1, 2026.

Magazines business recorded a 7.0% decline in net revenue in a structurally declining press market. The Group continues to manage its commercial investments selectively in order to preserve the recurring nature and quality of its revenues.

In Insurance, the strategic review under way is continuing in order to identify the most appropriate options to support the business’s long-term development as part of the Ambition 2030 plan.

First-half results

Consolidated revenue¹ amounted to €121.9m, up 3.9%, while net revenue² reached €90.3m, up 2.2%.

Restated EBITDA³ amounted to €11.9m, up 11.7% compared with a difficult first half of 2025. It represented 13.2% of first-half net revenue, compared with 12.0% in the first half of 2025, an improvement of 111 basis points.

Income from ordinary operations amounted to €8.1m, representing 8.9% of first-half net revenue, compared with €6.5m and 7.4% in the first half of 2025. EBIT also amounted to €8.1m, compared with €6.4m in the first half of 2025. These results notably reflect:

• solid growth in earnings from Agencies & Solutions, driven by the increasing contribution of international operations and the development of technology offerings;
• Consulting profitability remained affected by continued investment in international development, notably in the United States and Spain, and by increased investment in AI and technology, despite a slight improvement in project profitability;
• the lower contribution of the Magazines business to profitability, given the decline in the portfolio.

After a net financial expense of €0.5m and an income tax expense of €1.7m, consolidated net income amounted to €5.8m, representing a net margin of 6.4% of net revenue, compared with 4.2% in the first half of 2025.

After non-controlling interests, net income (Group share) amounted to €6.1m, up 58.9% compared with the first half of 2025.

(€m)	H1 2026	H1 2025	Change
Revenue	121.9	117.4	+3.9%
Net revenue	90.3	88.3	+2.2%
Restated EBITDA	11.9	10.6	+11.7%
As % of net revenue	13.2%	12.0%	+111 bp
Income from ordinary operations	8.1	6.5	+23.5%
As % of net revenue	8.9%	7.4%	+154 bp
EBIT	8.1	6.4	+25.3%
As % of net revenue	8.9%	7.3%	+164 bp
Net financial expense / income	(0.5)	(0.0)
Tax expense	(1.7)	(2.8)
Share of net income from associates	0.0	0.0
Consolidated net income	5.8	3.7	+57.2%
As % of net revenue	6.4%	4.2%	+223 bp
Net income (Group share)	6.1	3.8	+58.9%
As % of net revenue	6.7%	4.3%	+239 bp

Financial position at June 30, 2026

The Group’s shareholders’ equity at June 30, 2026 amounted to €55.6m, up €0.9m compared with December 31, 2025 (€54.7m).

Group cash amounted to €45.3m, compared with €55.0m at December 31, 2025 and €45.8m at June 30, 2025.

Financial debt amounted to €58.0m, down €3.2m compared with year-end 2025 (€61.2m). It includes commitments to buy out minority interests (€20.1m), down from year-end 2025 following additional share acquisitions in certain Group subsidiaries. It also includes €36.4m in bank borrowings, of which €26.2m was drawn under the syndicated credit facility established in November 2025.

Net cash/(debt)⁴ therefore amounted to €(12.7)m, compared with €(6.3)m at year-end 2025 and €(7.8)m at June 30, 2025, reflecting in particular the level of investment and external growth transactions completed over the past twelve months.

Outlook

Building on the momentum recorded in the first half, DEKUPLE Group is continuing to roll out its Ambition 2030 strategic plan, with the aim of accelerating its expansion in Europe while strengthening synergies between its areas of expertise.

The Group is actively developing its digital and international activities, continuing to industrialize marketing performance around the convergence of data, technology, artificial intelligence and creativity, and developing high-value recurring revenues.

Drawing on its financial resources and multi-expertise model, DEKUPLE Group will also continue an active policy of investment in technology and targeted external growth in order to strengthen its European leadership in Communication and Data Marketing.

Additional information

The corporate and consolidated financial statements for the first half of 2026 were approved by the Board of Directors on September 25, 2026. The financial statements have been subject to the usual limited review by the statutory auditors for half-year accounts. The half-year financial report will be published on September 30, 2026, after market close, and will be available on the company website at: https://www.dekuple.com/investisseurs/actualites-documents-presentations/

Next event

Revenue and net revenue for the third quarter of 2026, on November 23, 2026, before market opening.

About Dekuple Group

Dekuple Group is an international player in communication, marketing and data, driven by a unique multi-entrepreneurship model. Its integrated growth platform is built around three interconnected and complementary pillars:

• Advise, with Converteo and its 450 expert consultants
• Create, with its multi-expertise agencies in France and internationally
• Boost, with its Boost Factory bringing together its Data and MarTech solutions

With nearly 70 areas of expertise covering the entire communication and data marketing value chain, the Group supports brands in their differentiation and growth challenges. Its integrated approach, through a full-funnel ecosystem, makes it possible to optimize marketing investments and increase their impact.

Founded in 1972, Dekuple Group is present in Europe, North America, China and the Middle East. Its 1,200 employees support more than 750 major accounts and international mid-sized companies every day. Dekuple is listed on the regulated market of Euronext Paris.

www.dekuple.com

Financial Communications Contacts Actus Finance & Communication Cyril Combe – Analysts – Investors +33 1 53 65 37 94 Fatou-Kiné N’Diaye – Press – Media +33 1 53 67 36 34 dekuple@actus.fr

Dekuple Group Contact Investor Relations & Financial Information + 33 (0)1 41 58 72 03 relations.investisseurs@dekuple.com

---

1 Revenue (determined in line with the French professional status for subscription sales) only include the amount of remuneration paid by magazine publishers; for subscription sales, net sales therefore correspond to a net revenue (formerly gross margin), deducting the cost of magazines sold from the amount of sales recorded. For acquisition and management commissions linked to sales of insurance policies, net sales comprise current and future commissions issued, acquired by the accounting reporting date, net of cancellations.
2 For the digital marketing business, the net revenue (formerly gross margin) represents the total amount of net sales (total invoices issued: fees, commissions and purchases charged back to customers) less the total amount of costs for external purchases made on behalf of customers. It is equal to net sales for the magazines and insurance business lines.

3 EBITDA (earnings before interest, tax, depreciation and amortization) is restated for the IFRS 2 impact of bonus share awards and the IFRS 16 impact relating to the restatement of lease charges.
4 Cash position on the balance sheet net of all financial liabilities.

Attachment

• DEKUPLE_CP_resultats_semestriels_2026_E

LA HULPE, BELGIUM – 28 September 2026, 7:00 a.m. CEST – Banqup Group SA (Euronext: BANQ) (Banqup, Company), a European fintech provider that simplifies financial flows through an innovative secured platform for e-invoicing, e-payment, e-reporting and e-trust solutions with built-in compliance at its core, within a consortium led by Dubai-based Clever Science Computer System Trading Co. LLC, today announced the signing of a major agreement with the UAE Federal Tax Authority (“FTA”) to develop and implement Peppol Corner 5 Access Point.

Within the consortium, Banqup has been selected as a technology provider responsible for supporting the development, implementation and operation of the Peppol Corner 5 Access Point for the FTA. The UAE eInvoicing programme is governed by the Ministry of Finance as the regulatory and policy-making authority, while the FTA serves as the operational body responsible for implementation and administration of taxes in the UAE. The solution will adopt a 5-corner model to provide a structured and secure framework for processing e-invoices through a trusted network of interconnected parties, forming part of the broader UAE eInvoicing ecosystem that includes multiple accredited service providers and participants. It will be implemented in alignment with the Peppol standard and the requirements of the FTA. The UAE’s mandatory e-invoicing system will be rolled out in phases, initially covering both B2B and B2G transactions. The first phase is scheduled to begin on 1 January 2027 and will apply to companies with annual revenue exceeding AED 50 million.

This engagement marks an important step forward in advancing the UAE’s digital transformation agenda. Following this collaboration, the UAE becomes the first country to implement a fully Decentralised Continuous Transaction Control and Exchange (“DCTCE”) model using the Peppol framework. Serving as a key component of this next-generation platform, Banqup’s Corner 5 Peppol solution will enable seamless, secure, and standardised near-real-time exchange of e-invoices and tax data within the FTA’s infrastructure, supporting interoperability across the wider network of accredited eInvoicing service providers operating within the UAE framework.

The new infrastructure will enhance tax administration by reducing the VAT gap, ensuring compliance, and providing the FTA with near-real-time visibility. By automating and standardising invoicing and reporting processes, the solution will drive operational efficiency and fiscal transparency across the UAE.

The agreed project timeline spans seven months, commencing on 27 October 2025. Following the design and implementation phase, which was successfully completed in May 2026 making UAE FTA first ever Corner 5 based entirely on Peppol framework, Banqup will provide managed services and technical support, reinforcing its dedication to sustainable, scalable digital transformation in the public sector. 

Banqup’s selection reflects its proven expertise in delivering government e-invoicing infrastructure for tax administrations, combined with regulatory compliance experience across European markets. With its comprehensive (e-invoicing, e-reporting and e-trust) cloud-based and on-premise platforms, designed for national-scale deployment, Banqup is well positioned to support the delivery of this world-first Peppol-based DCTCE system as part of the UAE’s broader eInvoicing ecosystem.

Koen De Brabander, CEO of Banqup Group, said: “This flagship project with the UAE Federal Tax Authority further cements our position as a global leader in government-grade e-invoicing solutions. We are proud to support the UAE’s digital transformation strategy. Our proven expertise in delivering secure, interoperable, and future-proof invoicing platforms will support the broader network of stakeholders and accredited service providers working together to build a more efficient, compliant, and transparent fiscal ecosystem.

Contact

David Geleyn
Head of Investor Relations – Banqup Group
investor.relations@banqup.com
media@banqup.com 

About Banqup Group

Banqup Group (Euronext Brussels: BANQ) architects the trust infrastructure needed to thrive in a digital-first economy. As a specialized European fintech provider and licensed payment institution, Banqup revolutionizes buying and selling for businesses and governments worldwide by digitalising financial supply chain processes within a secure, tax-compliant business network.

Moving beyond traditional software, Banqup operates a unified, open network platform that links business actors, accounting networks, banks, ERP systems, and tax authorities. Built around four interconnected pillars—e-invoicing, e-payments, e-reporting, and e-trust—Banqup enables digitisation of end-to-end order-to-cash and procure-to-pay workflows in full compliance with different regulatory frameworks.

Headquartered in Belgium with a history of pioneering digital transformation since 2001, Banqup is powering growth through effortless financial flows.

To learn more, visit www.banqup.com.

Cautionary note regarding forward-looking statements: The statements contained herein may include prospects, statements of future expectations, opinions, and other forward-looking statements in relation to the expected future performance of Banqup Group and the markets in which it is active. Such forward-looking statements are based on management’s current views and assumptions regarding future events. By nature, they involve known and unknown risks, uncertainties, and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results, performance or events may, therefore, differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law, Banqup Group does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements.

Attachment

• Press Release – UAE

LA HULPE, BELGIUM – 28 September 2026, 7:00 a.m. CEST – Banqup Group SA (Euronext: BANQ) (Banqup, Company), a European fintech provider that simplifies financial flows through an innovative secured platform for e-invoicing, e-payment, e-reporting and e-trust solutions with built-in compliance at its core, within a consortium led by Dubai-based Clever Science Computer System Trading Co. LLC, today announced the signing of a major agreement with the UAE Federal Tax Authority (“FTA”) to develop and implement Peppol Corner 5 Access Point.

Within the consortium, Banqup has been selected as a technology provider responsible for supporting the development, implementation and operation of the Peppol Corner 5 Access Point for the FTA. The UAE eInvoicing programme is governed by the Ministry of Finance as the regulatory and policy-making authority, while the FTA serves as the operational body responsible for implementation and administration of taxes in the UAE. The solution will adopt a 5-corner model to provide a structured and secure framework for processing e-invoices through a trusted network of interconnected parties, forming part of the broader UAE eInvoicing ecosystem that includes multiple accredited service providers and participants. It will be implemented in alignment with the Peppol standard and the requirements of the FTA. The UAE’s mandatory e-invoicing system will be rolled out in phases, initially covering both B2B and B2G transactions. The first phase is scheduled to begin on 1 January 2027 and will apply to companies with annual revenue exceeding AED 50 million.

This engagement marks an important step forward in advancing the UAE’s digital transformation agenda. Following this collaboration, the UAE becomes the first country to implement a fully Decentralised Continuous Transaction Control and Exchange (“DCTCE”) model using the Peppol framework. Serving as a key component of this next-generation platform, Banqup’s Corner 5 Peppol solution will enable seamless, secure, and standardised near-real-time exchange of e-invoices and tax data within the FTA’s infrastructure, supporting interoperability across the wider network of accredited eInvoicing service providers operating within the UAE framework.

The new infrastructure will enhance tax administration by reducing the VAT gap, ensuring compliance, and providing the FTA with near-real-time visibility. By automating and standardising invoicing and reporting processes, the solution will drive operational efficiency and fiscal transparency across the UAE.

The agreed project timeline spans seven months, commencing on 27 October 2025. Following the design and implementation phase, which was successfully completed in May 2026 making UAE FTA first ever Corner 5 based entirely on Peppol framework, Banqup will provide managed services and technical support, reinforcing its dedication to sustainable, scalable digital transformation in the public sector. 

Banqup’s selection reflects its proven expertise in delivering government e-invoicing infrastructure for tax administrations, combined with regulatory compliance experience across European markets. With its comprehensive (e-invoicing, e-reporting and e-trust) cloud-based and on-premise platforms, designed for national-scale deployment, Banqup is well positioned to support the delivery of this world-first Peppol-based DCTCE system as part of the UAE’s broader eInvoicing ecosystem.

Koen De Brabander, CEO of Banqup Group, said: “This flagship project with the UAE Federal Tax Authority further cements our position as a global leader in government-grade e-invoicing solutions. We are proud to support the UAE’s digital transformation strategy. Our proven expertise in delivering secure, interoperable, and future-proof invoicing platforms will support the broader network of stakeholders and accredited service providers working together to build a more efficient, compliant, and transparent fiscal ecosystem.

Contact

David Geleyn
Head of Investor Relations – Banqup Group
investor.relations@banqup.com
media@banqup.com 

About Banqup Group

Banqup Group (Euronext Brussels: BANQ) architects the trust infrastructure needed to thrive in a digital-first economy. As a specialized European fintech provider and licensed payment institution, Banqup revolutionizes buying and selling for businesses and governments worldwide by digitalising financial supply chain processes within a secure, tax-compliant business network.

Moving beyond traditional software, Banqup operates a unified, open network platform that links business actors, accounting networks, banks, ERP systems, and tax authorities. Built around four interconnected pillars—e-invoicing, e-payments, e-reporting, and e-trust—Banqup enables digitisation of end-to-end order-to-cash and procure-to-pay workflows in full compliance with different regulatory frameworks.

Headquartered in Belgium with a history of pioneering digital transformation since 2001, Banqup is powering growth through effortless financial flows.

To learn more, visit www.banqup.com.

Cautionary note regarding forward-looking statements: The statements contained herein may include prospects, statements of future expectations, opinions, and other forward-looking statements in relation to the expected future performance of Banqup Group and the markets in which it is active. Such forward-looking statements are based on management’s current views and assumptions regarding future events. By nature, they involve known and unknown risks, uncertainties, and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results, performance or events may, therefore, differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law, Banqup Group does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements.

Attachment

• Press Release – UAE

Appointment of two highly respected sector leaders reflects a strong belief in the strategic and commercial value of the company’s technology and reinforces its ability to accelerate its path to market

Ghent, BELGIUM, Sept. 28, 2026 (GLOBE NEWSWIRE) —             Press Release

Biotalys (Euronext Brussels: BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, today announced the appointment of Christine Berwaerts and Ioana Tudor to its Board as independent directors. Christine Berwaerts will also assume the role of Chair of the Audit Committee, reinforcing the company’s financial governance as it continues to advance its strategic and commercial objectives.

The appointment of two new directors further broadens the experience and perspectives represented on the Biotalys Board. Following the appointments, the Board will comprise seven directors, including three women and four men, reflecting the company’s commitment to an appropriately balanced and diverse board composition.

Christine Berwaerts brings almost three decades of leadership experience in financial management, business operations and corporate governance across both the private and non-profit sectors. Most recently, she served as Chief Financial Officer of Globachem, a leading player in crop protection. Prior to that, she held senior financial leadership positions including Chief Financial Officer of Belchim Crop Protection Group, where she contributed to the company’s financial-operational development and international growth. In addition to her executive experience, Christine Berwaerts currently serves as a member of the Board of Directors of De Lijn, the Flemish public transport company and the social non-profit organization SAAMO Brussels.

Ioana Tudor has built an outstanding international career in agriculture, spanning crop protection, seeds, biotechnology and business development. She currently serves as Global Head of Crop Protection Marketing, Professional Solutions for Syngenta Crop Protection as well as holding regional accountability for Japan, Australia & New Zealand. Ms Tudor is also a member of Syngenta’s Crop Protection Leadership Team. During nearly 30 years with Syngenta, she has held numerous executive roles, including Global Head of Seedcare, Global Head of Diverse Field Crops and Vice President of Business Development for NAFTA Corn & Soybean seeds business, leading growth initiatives, innovation portfolios and strategic transactions across multiple agricultural sectors. Ioana Tudor also chairs the Crop Protection Strategy Council of CropLife International, the leading global trade association for the plant science industry, and serves on the board of the Folks Center for International Business at the University of South Carolina.  

Simon Moroney, Chairman of Biotalys, commented: “We are delighted to welcome Christine and Ioana to the Biotalys Board. They bring complementary experience and perspectives that will further strengthen the Board as Biotalys advances its strategic, regulatory and commercial ambitions. Christine’s extensive track record in financial leadership, governance and the crop protection industry will be particularly valuable in her additional role as Chair of the Audit Committee. Ioana’s deep expertise in crop protection innovation, global market development and strategic leadership will add further valuable capabilities to the Board as the company advances the commercialization of its protein-based biocontrol platform. Their appointments also mark another important step in building a diverse and well-balanced board capable of supporting the company through its next stage of development.”

Christine Berwaerts said: “Biotalys is pioneering a promising new generation of biological crop protection solutions to help growers address important agricultural challenges. I am excited to join the Board at this important stage in the company’s development and look forward to working closely with my fellow board members and the management team to support the company’s growth and strategic ambitions.”

Ioana Tudor added: ”The future of crop protection will require a broader range of innovative solutions that combine performance, sustainability and value for growers. Biotalys is developing a differentiated approach with significant potential, and I look forward to helping the company translate its scientific innovation into long-term commercial success.”

Effective 1 September 2026, Christine Berwaerts replaces Laura Meyer who resigned from the Board in March this year and, effective as of 28 September 2026, Ioana Tudor replaces Patrick Van Beneden who retired from the Board in June this year. Both appointments are done in accordance with article 7:88 § 1 of the Belgian Code of Companies and Associations and article 13 of the company’s articles of association and will be proposed for confirmation at the next shareholders meeting. Both Christine Berwaerts and Ioana Tudor will be presented as independent directors to the next shareholders meeting.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company developing precision biocontrol solutions based on proteins for the protection of crops in both the pre- and post-harvest markets. The company provides novel solutions that bridge the efficacy and scale of chemistry with the environmental advantages of biological solutions. Based on its novel AGROBODY® technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact:

Toon Musschoot, Investor Relations & Communications
T: +32 (0)9 274 54 00
E: IR@biotalys.com

Important Notice

Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company’s website.

This announcement contains statements which are “forward-looking statements” or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, ‘believe’, ‘estimate’, ‘anticipate’, ‘expect’, ‘intend’, “have the potential”, ‘may’, ‘will’, ‘plan’, ‘continue’, ‘ongoing’, ‘possible’, ‘predict’, ‘plans’, ‘target’, ‘seek’, ‘would’ or ‘should’, and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys’ actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

Appointment of two highly respected sector leaders reflects a strong belief in the strategic and commercial value of the company’s technology and reinforces its ability to accelerate its path to market

Ghent, BELGIUM, Sept. 28, 2026 (GLOBE NEWSWIRE) —             Press Release

Biotalys (Euronext Brussels: BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, today announced the appointment of Christine Berwaerts and Ioana Tudor to its Board as independent directors. Christine Berwaerts will also assume the role of Chair of the Audit Committee, reinforcing the company’s financial governance as it continues to advance its strategic and commercial objectives.

The appointment of two new directors further broadens the experience and perspectives represented on the Biotalys Board. Following the appointments, the Board will comprise seven directors, including three women and four men, reflecting the company’s commitment to an appropriately balanced and diverse board composition.

Christine Berwaerts brings almost three decades of leadership experience in financial management, business operations and corporate governance across both the private and non-profit sectors. Most recently, she served as Chief Financial Officer of Globachem, a leading player in crop protection. Prior to that, she held senior financial leadership positions including Chief Financial Officer of Belchim Crop Protection Group, where she contributed to the company’s financial-operational development and international growth. In addition to her executive experience, Christine Berwaerts currently serves as a member of the Board of Directors of De Lijn, the Flemish public transport company and the social non-profit organization SAAMO Brussels.

Ioana Tudor has built an outstanding international career in agriculture, spanning crop protection, seeds, biotechnology and business development. She currently serves as Global Head of Crop Protection Marketing, Professional Solutions for Syngenta Crop Protection as well as holding regional accountability for Japan, Australia & New Zealand. Ms Tudor is also a member of Syngenta’s Crop Protection Leadership Team. During nearly 30 years with Syngenta, she has held numerous executive roles, including Global Head of Seedcare, Global Head of Diverse Field Crops and Vice President of Business Development for NAFTA Corn & Soybean seeds business, leading growth initiatives, innovation portfolios and strategic transactions across multiple agricultural sectors. Ioana Tudor also chairs the Crop Protection Strategy Council of CropLife International, the leading global trade association for the plant science industry, and serves on the board of the Folks Center for International Business at the University of South Carolina.  

Simon Moroney, Chairman of Biotalys, commented: “We are delighted to welcome Christine and Ioana to the Biotalys Board. They bring complementary experience and perspectives that will further strengthen the Board as Biotalys advances its strategic, regulatory and commercial ambitions. Christine’s extensive track record in financial leadership, governance and the crop protection industry will be particularly valuable in her additional role as Chair of the Audit Committee. Ioana’s deep expertise in crop protection innovation, global market development and strategic leadership will add further valuable capabilities to the Board as the company advances the commercialization of its protein-based biocontrol platform. Their appointments also mark another important step in building a diverse and well-balanced board capable of supporting the company through its next stage of development.”

Christine Berwaerts said: “Biotalys is pioneering a promising new generation of biological crop protection solutions to help growers address important agricultural challenges. I am excited to join the Board at this important stage in the company’s development and look forward to working closely with my fellow board members and the management team to support the company’s growth and strategic ambitions.”

Ioana Tudor added: ”The future of crop protection will require a broader range of innovative solutions that combine performance, sustainability and value for growers. Biotalys is developing a differentiated approach with significant potential, and I look forward to helping the company translate its scientific innovation into long-term commercial success.”

Effective 1 September 2026, Christine Berwaerts replaces Laura Meyer who resigned from the Board in March this year and, effective as of 28 September 2026, Ioana Tudor replaces Patrick Van Beneden who retired from the Board in June this year. Both appointments are done in accordance with article 7:88 § 1 of the Belgian Code of Companies and Associations and article 13 of the company’s articles of association and will be proposed for confirmation at the next shareholders meeting. Both Christine Berwaerts and Ioana Tudor will be presented as independent directors to the next shareholders meeting.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company developing precision biocontrol solutions based on proteins for the protection of crops in both the pre- and post-harvest markets. The company provides novel solutions that bridge the efficacy and scale of chemistry with the environmental advantages of biological solutions. Based on its novel AGROBODY® technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact:

Toon Musschoot, Investor Relations & Communications
T: +32 (0)9 274 54 00
E: IR@biotalys.com

Important Notice

Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company’s website.

This announcement contains statements which are “forward-looking statements” or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, ‘believe’, ‘estimate’, ‘anticipate’, ‘expect’, ‘intend’, “have the potential”, ‘may’, ‘will’, ‘plan’, ‘continue’, ‘ongoing’, ‘possible’, ‘predict’, ‘plans’, ‘target’, ‘seek’, ‘would’ or ‘should’, and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys’ actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.